Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice

Hypertension

Volumn 61, Issue 1, 2013, Pages 120-129

  López Andrés, Natalia ^a   Calvier, Laurent ^a   Labat, Carlos ^a   Fay, Renaud ^b,c,d   Díez, Javier ^e   Benetos, Athanase ^a,c   Zannad, Faiez ^a,b,c,d   Lacolley, Patrick ^a   Rossignol, Patrick ^a,b,c,d  

^a INSERM   (France)

^b CIC9501   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d UNIVERSITY OF NAVARRA   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

aging; cytokines; fibrosis; vascular stiffness

Indexed keywords

CARDIOTROPHIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERIAL FIBROSIS; ARTERIAL STIFFNESS; ARTERY DISEASE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; IMMUNOHISTOCHEMISTRY; LIFESPAN; LONGEVITY; MALE; MORPHOLOGY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; SMOOTH MUSCLE FIBER; SURVIVAL RATE; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; WILD TYPE; YOUNG MODULUS;

ANIMALS; APOPTOSIS; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; CELL AGING; CELLS, CULTURED; CYTOKINES; FIBROSIS; LONGEVITY; MALE; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RATS; VASCULAR STIFFNESS;

EID: 84871613231     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.201699     Document Type: Article

References (31)

1. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM, Darbonne WC, Knutzon DS, Yen R, Chien KR. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA. 1995;92:1142-1146.
2. Lopez-Andres N, Fortuno MA, Diez J, Zannad F, Lacolley P, Rossignol P. Vascular effects of cardiotrophin-1: a role in hypertension? J Hypertens. 2010;28:1261-1272.
3. Lopez-Andres N, Rousseau A, Akhtar R, et al. Cardiotrophin 1 is involved in cardiac, vascular, and renal fbrosis and dysfunction. Hypertension. 2012;60:563-573.
4. López B, González A, Lasarte JJ, Sarobe P, Borrás F, Díaz A, Barba J, Tomás L, Lozano E, Serrano M, Varo N, Beloqui O, Fortuño MA, Díez J. Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens. 2005;23:625-632. (Pubitemid 40684722)
5. López B, González A, Querejeta R, Barba J, Díez J. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. J Hypertens. 2009;27:418-424.
6. Talwar S, Squire IB, Downie PF, Davies JE, Ng LL. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart. 2000;84:421-424.
7. Talwar S, Squire IB, O'Brien RJ, Downie PF, Davies JE, Ng LL. Plasma cardiotrophin-1 following acute myocardial infarction: relationship with left ventricular systolic dysfunction. Clin Sci (Lond). 2002;102:9-14. (Pubitemid 34177795)
8. Talwar S, Downie PF, Squire IB, Davies JE, Barnett DB, Ng LL. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail. 2001;3:15-19. (Pubitemid 32127104)
9. Lakatta EG. Cardiovascular regulatory mechanisms in advanced age. Physiol Rev. 1993;73:413-467.
10. Serrano M, Blasco MA. Putting the stress on senescence. Curr Opin Cell Biol. 2001;13:748-753. (Pubitemid 33042736)
11. Wei JY. Age and the cardiovascular system. N Engl J Med. 1992;327:1735-1739.
12. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation. 2003;107:490-497. (Pubitemid 36158054)
13. Lakatta EG, Wang M, Najjar SS. Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am. 2009;93:583-604, Table of Contents.
14. Spinetti G, Wang M, Monticone R, Zhang J, Zhao D, Lakatta EG. Rat aortic MCP-1 and its receptor CCR2 increase with age and alter vascular smooth muscle cell function. Arterioscler Thromb Vasc Biol. 2004;24:1397-1402. (Pubitemid 39050431)
15. Wang M, Zhao D, Spinetti G, Zhang J, Jiang LQ, Pintus G, Monticone R, Lakatta EG. Matrix metalloproteinase 2 activation of transforming growth factor-beta1 (TGF-beta1) and TGF-beta1-type II receptor signaling within the aged arterial wall. Arterioscler Thromb Vasc Biol. 2006;26:1503-1509. (Pubitemid 44288975)
16. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fbronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation. 2002;106:2848-2853. (Pubitemid 35396986)
17. López-Andrés N, Martin-Fernandez B, Rossignol P, Zannad F, Lahera V, Fortuno MA, Cachofeiro V, Díez J. A role for cardiotrophin-1 in myocar-dial remodeling induced by aldosterone. Am J Physiol Heart Circ Physiol. 2011;301:H2372-H2382.
18. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiol-ogy, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25:932-943. (Pubitemid 40627836)
19. Lacolley P, Challande P, Osborne-Pellegrin M, Regnault V. Genetics and pathophysiology of arterial stiffness. Cardiovasc Res. 2009;81:637-648.
20. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236-1241. (Pubitemid 34163575)
21. Walker EC, McGregor NE, Poulton IJ, Pompolo S, Allan EH, Quinn JM, Gillespie MT, Martin TJ, Sims NA. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res. 2008;23:2025-2032.
22. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, Sudano I, Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation. 1995;91:1981-1987.
23. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239-247.
24. Sauer H, Neukirchen W, Rahimi G, Grünheck F, Hescheler J, Wartenberg M. Involvement of reactive oxygen species in cardiotrophin-1-induced proliferation of cardiomyocytes differentiated from murine embryonic stem cells. Exp Cell Res. 2004;294:313-324. (Pubitemid 38326733)
25. Campisi J. Cancer and aging: yin, yang, and p53. Sci Aging Knowledge Environ. 2002;2002:pe1.
26. Hasty P, Campisi J, Hoeijmakers J, van Steeg H, Vijg J. Aging and genome maintenance: lessons from the mouse? Science. 2003;299:1355-1359. (Pubitemid 36254641)
27. Moreno-Aliaga MJ, Pérez-Echarri N, Marcos-Gómez B, Larequi E, Gil-Bea FJ, Viollet B, Gimenez I, Martínez JA, Prieto J, Bustos M. Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab. 2011;14:242-253.
28. Zolk O, Engmann S, Münzel F, Krajcik R. Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue. Am J Physiol Endocrinol Metab. 2005;288:E1214-E1221. (Pubitemid 40726809)
29. Fritzenwanger M, Meusel K, Jung C, Franz M, Wang Z, Foerster M, Figulla HR. Cardiotrophin-1 induces tumor necrosis factor alpha synthesis in human peripheral blood mononuclear cells. Mediators Infamm. 2009;2009:489802.
30. Zvonic S, Hogan JC, Arbour-Reily P, Mynatt RL, Stephens JM. Effects of cardiotrophin on adipocytes. J Biol Chem. 2004;279:47572-47579. (Pubitemid 39540902)
31. Natal C, Fortuño MA, Restituto P, Bazán A, Colina I, Díez J, Varo N. Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. Am J Physiol Endocrinol Metab. 2008;294: E52-E60.